• Olynka Vega-Vega, Noemí Del Toro-Cisneros, Víctor M Sacoto-Romo, Juan M Ardavín-Ituarte, Alicia Piñeirúa-Menéndez, José C Peña-Rodríguez, Jesús M Ramos-Gordillo, Giovanna Y Arteaga-Müller, Héctor J Mayorga-Madrigal, Ricardo Mendiola-Fernández, Néstor H Cruz Mendoza, Mauricio Arvizu-Hernández, and Ricardo Correa-Rotter.
• Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
• Rev Invest Clin. 2022 Jan 1; 75 (2): 475247-52.

BackgroundSince the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, patients with chronic kidney disease vulnerable to suffering more severe COVID-19 disease and worse outcomes have been identified.ObjectivesOur study's aim was to determine the incidence, characteristics, and outcomes of SARS-CoV-2 infection in patients of hemodialysis (HD) units in Mexico and to describe the availability of confirmatory testing.MethodsThis study was multicentric study of 19 HD units, conducted between March 2020 and March 2021.ResultsFrom a total of 5779 patients, 955 (16.5%) cases of suspicious COVID-19 were detected; a SARS-CoV-2 reverse transcription polymerase chain reaction test was done in only 50.6% of patients. Forty-five percentages were hospitalized and 6% required invasive mechanical ventilation (IMV). There was no significant difference in mortality between confirmed (131/483) and suspicious (124/472) cases (p = 0.74). The percentage of patients in need of hospitalization, IMV, and deceased was greater than in the rest of the study population.ConclusionsThe study revealed that 49.4% of the cases were not confirmed, a worrisome observation given that this is a highly vulnerable population (higher probability of contagion and worse outcomes), in which 100% of patients should have a confirmatory test.Copyright: © 2022 Permanyer.

10 keywords...

hide…